ARCHIVES

Clolar Approved for Pediatric Refractory/Relapsed ALL

This article is from The Cancer Letter archive.

Vol. 28 No. 1 | January 28, 2005

Download PDF Visit The Full Archive

Related Articles

In Brief: RFP Offers Patent Rights Instead Of Profit; ACS, NCI Plan More Joint Projects; BC Report Sept. 30

September 20, 1974

Merck Serono Cancels Tecemotide Program In NSCLC, Including Two Phase III Trials

September 26, 2014

Tamoxifen: No Mortality Benefit For Most “High Risk” Women

September 29, 2006

NCI Proposal Would Give Drug Sponsors Commercial Rights To Biomarker Inventions

October 16, 2009

In Turnaround, HHS Says It Will Enforce Pediatric Rule

April 26, 2002

Professional Societies: Organizations Form Alliance To Call For Quality Cancer Care

October 9, 1998